Hollow mesoporous silica nanoparticles as delivery vehicle of foot-and-mouth disease virus-like particles induce persistent immune responses in guinea pigs

Manyuan Bai1 | Hu Dong1 | Xin Su1,2 | Ye Jin1 | Shiqi Sun1 | Yingpeng Zhang2 | Yunshang Yang2 | Huichen Guo1

1State Key Laboratory of Veterinary Etiological Biology and Key Laboratory of Animal Virology of Ministry of Agriculture, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou, Gansu, P. R. China
2School of Petrochemical Engineering, Lanzhou University of Technology, Lanzhou, P. R. China

Correspondence
Huichen Guo, State Key Laboratory of Veterinary Etiological Biology and Key Laboratory of Animal Virology of Ministry of Agriculture, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Xujiaping 1, 730046 Lanzhou, Gansu, P. R. China.
Email: guohuichen@caas.cn.

Funding information
National Key Research and Development Program of China, Grant/Award Numbers: 2016YFE0204100, 2017YFD0501100, 2017YFD0500900; Elite Youth program of Chinese Academy of Agricultural Sciences

Abstract
Foot-and-mouth disease (FMD) is an acute and febrile infectious disease, which can cause great economic losses. Virus-like particles (VLPs) as an advantageous antigen can induce significant specific immune response. To improve immunity of VLPs, especially, make it induce persistent immune response, the hollow mesoporous silica nanoparticles (HMSNs) as a potential nano-adjuvant were synthesized and loaded the FMD virus (FMDV) VLPs. They were injected into guinea pigs and the specific immune response was detected. The results confirmed that HMSNs/VLPs can induce persistent humoral immunity with high-level antibody titer for more than three months. HMSNs also improve the T-lymphocyte proliferation and IFN-γ induced by FMDV VLPs, and provides the ideal protection against FMDV challenge. These consequences indicated that HMSNs were good protein delivery vehicle and potential nano-adjuvant of vaccines.

KEYWORDS
foot-and-mouth disease, guinea pigs, hollow mesoporous silicananoparticles, immunization, virus-like particles

1 | INTRODUCTION

Foot-and-mouth disease (FMD) is a communicable disease of cloven-hoofed animals that results in major economic losses during disease outbreaks.1,2 The economic losses reported for five previous FMD epidemics from 2000 to 2011 in the Republic of Korea ranged from $23.6 million to $1.9 billion.3 The annual production losses and vaccination costs of FMD are estimated to be approximately 21 billion globally.4,5 Thus, the prevention and control of FMD are crucial. Traditional vaccines for this disease have partly reduced the frequency of FMD virus (FMDV) epidemics, but limitations and problems impede proper disease elimination.

With the development of genetic engineering technology, various new vaccines, such as synthetic peptide vaccine and recombinant vaccine, have been introduced. The lack of viral genetic material is the common feature of new vaccines, which can then be used to purify the pathogens. Virus-like particles (VLPs), as a representative of new vaccines, are composed of one or more viral structural proteins and lack viral genetic material. Following the emergence of HBV-VLPs, an increasing number of VLPs vaccines, such as HPV-VLPs and HEV-VLPs vaccines, have been successively approved by the FDA. Thus, VLPs are increasingly considered as the most promising candidate vaccines.6–8 However, recombinant vaccines possess some defects, such as antigenic instability and short immunization cycle. Hence, developing
safer and more efficient adjuvants than those currently available can address the shortcomings of new vaccines.\textsuperscript{9,10}

Nanoparticles can be designed for targeted antigen delivery to immune cells and stimulate the immune response to promote antigen immunogenicity. Thus, they are usually applied for developing nanovaccines and drug carriers. Nanoadjuvants are fabricated from nanosized particle materials. Nanoadjuvants exhibit strong adsorptive abilities, good slow-release function, and effective targeting and thermal stability.\textsuperscript{11} At present, numerous nanoadjuvants have been developed. These materials include mesoporous silica nanoparticles, liposomes, calcium phosphate, aluminum hydroxide, polyactic glycolic acid, and poly-lactic acid.\textsuperscript{12-14} Hollow mesoporous silica nanoparticles (HMSNs), as drug delivery vehicles, possess relatively large surface areas, adjustable pore sizes, high surface paintability, controlled release capability, and good thermal stability. These properties are suitable for an ideal gene/drug delivery vehicle.\textsuperscript{15-17}

In this study, specific and persistent immune responses were achieved by adsorbing FMDV VLPs onto HMSNs prepared by a sol-gel/emulsion (oil-in-water/ethanol) method. Then, guinea pigs were immunized with HMSNs/VLPs, and the resultant immune responses were evaluated. Compared with the immune responses of the animals immunized with VLPs/Freund’s complete adjuvant, those of the animals immunized with HMSNs/VLPs were stronger and more persistent. The results confirmed that HMSNs should be further studied as protein delivery vehicles to develop new-generation adjuvants.

2 | MATERIALS AND METHODS

2.1 | Synthesis and characterization of HMSNs

The HMSNs were synthesized using a sol-gel/emulsion (oil-in-water/ethanol) method.\textsuperscript{15,18} First, 42 mL of ethanol, 79.5 mL of H$_2$O, 1.5 mL of tetraethoxysilane (Aladdin, Shanghai, China), and 0.24 g of hexadecyltrimethylammonium bromide (YW, Wuhan, China) were mixed and stirred continuously. Then, 1.5 mL of ammonium solution (25 wt% NH$_3$ in water) was added, and the mixture was shaken or stirred (10,000 rpm) for 6 hours and stored for 24 hours at room temperature. Afterward, the HMSNs were washed several times with deionized water and ethanol and centrifuged at 8000 to 10,000 rpm for 15 to 20 minutes. The final product was calcined in air at 200°C for 6 hours and then at 600°C for 6 hours.

The morphological characteristics of the HMSNs were detected by dynamic light scattering (DLS; Malvern Instruments Ltd, Worcestershire, UK) and transmission electron microscopy (TEM). For DLS, the incident angle was 90°, and the incident wavelength of the laser was 633 nm. Each sample was measured three times at room temperature, and the average particle diameter was expressed as mean ± standard deviation (SD). TEM samples were prepared by dipping a drop of the solution onto carbon-film-coated copper grids and staining with phosphotungstic acid. Then, a JEOL electron microscope (Tokyo, Japan) was used to observe the samples at an acceleration voltage of 100 kV. The Barrett-Joyner-Halenda (BJH) method was applied to detect the total pore volume and pore diameter of HMSNs. The surface area of HMSNs was obtained using the Brunauer-Emmett-Teller (BET) method.\textsuperscript{19}

2.2 | Assembly and detection of VLPs

The FMDV VLPs were produced and detected as described previously.\textsuperscript{8,20} The SUMO (Smt3) gene and FMDV capsid proteins VP0, VP1, and VP3 genes were subcloned into pET-28a, and then the recombinant plasmids were transformed into Escherichia coli BL21 (DE3). The transformed E. coli was cultivated at 37°C in Lysogeny broth medium and induced by isopropyl $\beta$-D-1-thiogalactopyranoside and then the fusion proteins were eluted with Buffer A (500 mM NaCl, 5% glycerinum, 200 mM Tris-HCl, 1% Triton-X100, and 500 mM imidazole, pH 8.0). The SUMO-tag of fusion proteins was cleaved by SUMO protease and the FMDV capsid proteins VP0, VP1, and VP3 can self-assemble into VLPs in the buffer B (400 mM Tris-HCl, 250 mM NaCl, 1 mM CaCl$_2$, and 1 mM dithiothreitol, pH 8.0) for 24 hours at 4°C. Then, the samples were centrifuged by sucrose gradient ultracentrifugation method, and the fraction was used for dynamic light scattering instrument (DLS) and transmission electron microscope (TEM).

2.3 | VLP adsorption of HMSNs

VLPs were adsorbed to HMSNs as described previously.\textsuperscript{17} HMSNs (0.5 mg/mL) were sonicated for 15 minutes and mixed with different concentrations of FMDV VLPs (125, 150, 175, 200, 225, and 250 µg/mL) at 4°C. After 4 and 16 hours, the solutions were centrifuged at 10,000 rpm for 5 minutes, and the proteins of the supernatant and sediments were measured by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Then, SDS-PAGE results were analyzed by the ImageJ software (National Institutes of Health, Bethesda, MD). The amount of proteins adsorbed by the HMSNs was estimated from the amount of proteins in the sediment.

2.4 | Size of the HMSNs/VLPs mixture

The size of the HMSNs/VLPs mixture was detected by DLS (Malvern Instruments Ltd). HMSNs (2 mg) was dispersed into PBS (1 mL) to obtain the final concentration 2 mg/mL. Then 0.25 mL HMSNs(2 mg/mL) was mixed with 0.25 mL VLPs (800 µg/mL).

2.5 | Release kinetics of HMSNs

HMSNs/VLPs were suspended in PBS (pH 7.0), and the solution was maintained at 37°C. At different time points, samples were obtained for centrifugation (10,000 rpm, 5 minutes). The amount of protein released by HMSNs was detected with a Bradford protein assay kit (Beyotime Biotechnology, Shanghai, China).

2.6 | Animal immunization and challenge protocols

Guinea pigs (300-400 g) were purchased from the Lanzhou Veterinary Research Institute and raised in isolation cages. These animals were then cared for in accordance with the regulations of the Animal Research Ethics Board of Lanzhou Veterinary Research Institute.
CAAS, China. The guinea pigs were randomized into six groups and immunized as described in Table 1. The animals were each intramuscularly immunized in the tibialis cranialis muscle of both rear legs, and serum samples were gathered every two weeks from the heart of each guinea pig. Preexperiment confirmed that the challenge viral dose and 50% infectious dose for the guinea pigs were 0.2 and 10-6.5/0.2 mL, respectively. Then, 0.2 mL aliquots of homologous live virus solution diluted from 10 to 6.5 were subcutaneously and intradermally injected into the interdigital skin lesion on the back as an indicator of total protection. On both back soles as an indicator of no protection and no protection, on the left back leg was considered to as an indicator of partial protection. The lesion appearing only on the left back leg was considered to as an indicator of partial protection, on both back soles as an indicator of no protection and no lesion on the back as an indicator of total protection.

2.7 Enzyme-linked immunosorbent assay

Serum samples collected weekly from the guinea pigs were evaluated by enzyme-linked immunosorbent assay (ELISA). Initially, a 96-well ELISA microplate (Corning Incorporated, Corning, ME) was coated with 100 µL of FMDV 146S antigen in 0.05 M of NaHCO3 coating buffer (pH 9.6) and incubated at 4°C overnight. After washing with phosphate buffered saline with Tween 20 (PBST) three times, the microplate was blocked with 120 µL of PBST containing 1% bovine serum albumin for 1 hour at 37°C. Then, 100 µL of diluted serum (1:32) with PBST was incubated for 1 hour at 37°C, washed three times with PBST, and then patted dry. Afterward, 100 µL of HRP-labeled rabbit anti-guinea pig IgG (Sigma-Aldrich, St. Louis, MO) was incubated as described above, followed by incubation with 100 µL of O-phenylenediamine/hydrogen peroxide (H2O2) for 15 minutes at 37°C. The color reaction was stopped with 100 µL of 2 N H2SO4, and the optical density (OD) value was read using an ELISA reader (Bio-Rad, CA, USA) at 490 nm.

2.8 T-lymphocyte proliferation assay

Spleens were collected from immunized guinea pigs, and then spleen cells were resuspended in RPMI 1640 medium. Lymphocyte separation medium (Sangon, China) was added, and the mixture was centrifuged at 1000 to 2000 rpm for 5 minutes. A straw was used to carefully extract the lymphocyte layer into the centrifuge tube, and then the lymphocytes were washed three times with RPMI 1640 medium. T-lymphocytes in 96-well plates (5 x 10^6 cells per well) were added to 100 µL of 50 µg/mL ConA, 150 µg/mL ConA, and RPMI 1640 and incubated at 37°C under 5% CO2 for 68 hours. Next, 3-(4,5-dimethylthiazol-2-yi)-3,5-diphenyltetrazolium bromide (MTT)/PMS mixture was added to each well, and the mixture was incubated at 37°C under 5% CO2 for 4 hours. The OD value was measured at 490 nm, and the stimulus index was calculated to reveal the level of T-lymphocyte proliferation.

2.9 Detection of IFN-γ

The guinea pig IFN-γ levels in serum samples were determined by using a guinea pig IFN-γ ELISA kit (Ziker, Shenzhen, China) in accordance with the manufacturer’s instructions. Initially, BSA was diluted to 9, 6, 3, 1.5, and 0.75 mmol/L and added to an ELISA plate (50 µL per well). Then, serum samples were diluted (1:5) and added to each well (50 µL). Measurements were performed in duplicate, and the OD450 was attained using an ELISA reader.

2.10 Statistical analysis

Results among groups were presented as means and SDs; P < 0.05 was regarded as statistically significant. Statistical analysis was performed with GraphPad Prism (Version 5.0). Kruskal-Wallis H test was then used to evaluate specific and neutral antibody immune responses. Significant differences in T-lymphocyte immune responses among groups were determined using the Student t test.

3 RESULTS

3.1 Characterization of HMSNs

HMSNs were uniformly spherical particles (Figure 1A and 1B), with an average spherical diameter of approximately 400 nm (Figure 3C). The HMSN surface area was 1035.73 m^2/g, which was obtained using the BET method (Figure 1C). The pore volume and aperture size of spherical particles were 0.57 cm^3/g and 22.07 Å (approximately 2.2 nm), respectively, which were obtained by the BJH method (Figure 1D). The diameters of the HMSNs/VLPs significantly increased relative to those of the HMSN control. The results also suggest that to some extent the HMSN surface can adsorb a large amount of VLPs.

3.2 Determination of FMDV VLPs

After the assembly of FMDV VLPs in the assembly buffer, the product was filtered, and the product’s molecular size was determined by DLS. The products were then negatively stained and visualized through TEM. The results indicated that the FMDV VLPs were uniform hollow particles, and the average VLP diameter was approximately 20 nm (Figure 2).

| TABLE 1 Immunization groups in guinea pigs study | Treatment group | Group description | Injected dose |
|-----------------------------------------------|-----------------|------------------|---------------|
| 1                                             | PBS             | PBS (0.25 mL)    |
| 2                                             | HMSN            | HMSN (0.5 mg)    |
| 3                                             | VLP + Freund’s complete adjuvant | VLP (100 µg)     |
| 4                                             | HMSN/VLP1       | HMSN/VLP (0.5 mg/100 µg) |
| 5                                             | HMSN/VLP2       | HMSN/VLP (0.5 mg/200 µg) |
| 6                                             | Unimmunized control | N/A               |

Abbreviations: HMSNs, hollow mesoporous silica nanoparticles; PBS, phosphate buffered saline; VLP, virus-like particles. All doses were injected intramuscularly.
3.3 Adsorption and release kinetics of HMSNs/VLPs

The quantity of VLPs that adsorbed onto the HMSN surfaces was measured by detecting the FMDV VLPs from the supernatant and sediment. With the increased VLPs proportion, the amount of VLPs remaining in the solution also increased at 4°C for 4 and 16 hours. But, compared with 4 hours, the amount of VLPs remaining in the solution was lower and the amount of VLPs loaded on HMSNs in the precipitation was higher for 16 hours, which means that HMSNs can load more VLPs at 4°C for 16 hours than 4 hours. Given the results, 0.5 mg/200 µg of HMSNs/VLPs was selected as the optimal proportion at 4°C incubation for 16 hours (Figure 3A and 3B). DLS results showed that the size of HMSNs/VLPs was approximately 1 µm, which indicates that numerous VLPs were adsorbed on the HMSNs (Figure 3C). Based on the results of VLPs released from HMSNs/VLPs, approximately 50% of the VLPs were released at day 9. The HMSNs also exhibited a good ability to release proteins slowly (Figure 3D).

3.4 Specific antibody in guinea pigs

To evaluate the adjuvant effect of HMSNs, the specific antibody responses were quantified by ELISA. The level of specific antibodies of guinea pigs immunized with VLPs/Freund’s complete adjuvant greatly increased at the fourth week and reached the peak at the 10th week and then decreased significantly. The group immunized with HMSNs/VLPs showed the same trend as that of the former, but the antibody titers of the group vaccinated with the HMSNs/VLPs (200 µg) were significantly higher than those of the former at the 14th week. Similarly, the antibody titers of the group vaccinated with HMSNs/VLPs (200 µg) were higher than those of the group vaccinated with the HMSNs/VLPs (100 µg). Overall, the findings...
indicated that the HMSNs exert a better slow-release effect than the Freund’s complete adjuvant (Figure 4).

3.5 | T-lymphocyte proliferation assay

MTT was used to measure T-lymphocyte proliferation. The results showed that the proliferative capacity of the group immunized with HMSNs/VLPs at the seventh week was significant ($P < 0.05$) than those in the PBS or HMSN control group. T-lymphocyte proliferation was more evident in the group immunized with HMSNs/VLPs than in the group immunized with VLPs/Freund’s complete adjuvant. The results demonstrated that the HMSN as carriers and adjuvant can induce the body to produce humoral and cellular immune responses, similar to that in traditional adjuvants (Figure 5).

3.6 | Guinea pig serum IFN-γ levels

A guinea pig IFN-γ ELISA kit was adopted to test the levels of IFN-γ induced by VLPs. The results indicated that the levels of IFN-γ were increased significantly in the guinea pigs vaccinated with HMSNs/VLPs at the second ($P < 0.05$) to fourth ($P < 0.05$) weeks compared with PBS or HMSN control group. The IFN-γ levels in the group immunized with VLPs/Freund’s complete adjuvant reached the maximum value at the second week ($P < 0.05$). However, the IFN-γ levels in the group immunized with HMSNs/VLPs (200 µg) gradually increased and exceeded those of the group immunized with VLPs from the second to fourth weeks (Figure 6).

3.7 | Protective test against FMDV in guinea pigs

Table 2 shows that all the guinea pigs were infected in the groups immunized with PBS, HMSN, and blank control. Compared with the group immunized with HMSNs/VLPs (100 µg), the protection rates of groups immunized with HMSNs/VLPs (200 µg) and VLPs/Freund’s complete adjuvant were higher (80%). This result indicated that the protection rate was positively correlated with the antigen immune dose.
FIGURE 6 IFN-γ was detected from immunized guinea pig serum. Guinea pig serum was collected at one, two, three, and four weeks after immunization. Results represent the means ± SDs. HMSNs, hollow mesoporous silica nanoparticles; PBS, phosphate buffered saline; VLP, virus-like particles.

TABLE 2 Statistical analysis of the incidence of guinea pigs

| Days | Treatment Group |
|------|-----------------|
|      | PBS | HMSN | Freund<sup>a</sup> | VLP<sup>b</sup> | VLP<sup>c</sup> | Control<sup>d</sup> |
| 1    | −−−− | −−−− | −−−−− | −−−− | −−−−− | −−−−− |
| 2    | −−−− | −−−− | −−−−− | −−−− | −−−−− | −−−−− |
| 3    | +++++ | ++++ | −−−−− | ++++ | −−−− | +++++ |
| 4    | +++++ | ++++ | −−−− | +++++ | −−− | +++++ |
| 5    | +++++ | ++++ | −−−− | +++++ | −−− | +++++ |
| 6    | +++++ | ++++ | −−−− | +++++ | −−− | +++++ |
| 7    | ++ ++ | ++++ | −−−− | +++++ | −−− | +++++ |

Abbreviations: HMSNs, hollow mesoporous silica nanoparticles; PBS, phosphate buffered saline; VLPs, virus-like particles.

Thirty guinea pigs were randomized into six groups of five animals each. Each "−" or "+" symbol means one of guinea pig; "−" is a guinea pig that no lesion on the back legs; "+" is a guinea pig that the lesion appearing only on the left back sole or both back soles.

Protection rates (%) = number of total protected guinea pigs per group/total number of guinea pigs per group × 100%.

<sup>a</sup>VLPs/Freund’s adjuvant.
<sup>b</sup>HMSNs/VLPs (100 µg).
<sup>c</sup>HMSNs/VLPs (200 µg).
<sup>d</sup>Unimmunized blank control.
4 | DISCUSSION

Compared with the inactivated vaccines, VLPs are secure candidate vaccines that possess the following characteristics. First, these particles can be used to purify the pathogen because the material does not contain any genome. Second, fabricating VLPs is simple, cheap, and suitable for veterinary vaccine production. Previous works have confirmed that VLPs, as immunological antigens, can induce strong immune responses with the aid of traditional adjuvants. In the present study, HMSNs, as new adjuvants or delivery vehicles of FMDV VLP vaccine, were further evaluated in comparison with traditional adjuvants.

In recent years, nanomaterials have been extensively applied in the biological field. They exhibit strong adsorption properties, good slow-release function, effective targeting, and thermal stability, which have attracted the attention of researchers. Nanoadjuvants have been used as protein delivery vehicles to induce efficient and persistent immune responses. HMSNs, as new nanomaterials, were synthesized by using the sol-gel/emulsion (oil-in-water/ethanol) method. They are uniformly spherical particles with good dispersion in solution. They also possess large surface areas, which are beneficial for protein adsorption. Through the BJH method, the pore and aperture sizes of the HMSNs were found to be 0.57 cm$^3$/g and 22.07 Å (approximately 2.2 nm), respectively. These unique structural characteristics determined the HMSNs’ strong adsorption capacity. Adsorption kinetic experiments indicated that the adsorption capacity of the HMSNs reached up to 300 μg/mg (VLPs/HMSNs). This result may be dependent on the large surface area of HMSNs and the high-density charge distribution on the VLPs surface. Thus, the HMSNs dosage is greatly decreased as vaccine adjuvant.

The immune response level can be reflected by specific antibody titers. Release kinetics assay showed that VLPs can be released in a sustained manner in the solution; the continuous release of VLPs can induce a persistent immune response. Therefore, the specific antibody titers increased significantly. Statistical results of ELISA showed that the specific antibody titers of the group vaccinated with HMSNs/VLPs were significantly higher than those of the group vaccinated with VLPs/Freund’s complete adjuvant at the 14th week. The antibody titers of the group vaccinated with the HMSNs/VLPs (200 μg) were also higher than those of the group vaccinated with HMSNs/VLPs (100 μg). These results indicated that HMSNs can induce a more persistent immune response than Freund’s complete adjuvant. To a large extent, the sustained stimulus responses were achieved mainly depending on the low release effect of the HMSNs. In this case, the immune dose could be reduced significantly. T-cell activation and cytokines also play key roles in immune protection. IFN-γ is a key cytokine related to the activation of macrophages and T-lymphocytes; it can efficiently inhibit early FMDV infection and replication. IFN-γ is produced only by activated T cells and natural killer cells, which are the symbolic cytokines of Th1 cells. In this study, the levels of T-lymphocyte and IFN-γ from the groups immunized with HMSNs/VLPs were significantly higher than those of the other groups. Protective tests against FMDV showed that the immune response induced by HMSNs/VLPs provided a favorable immune protection rate. All results confirmed that the HMSNs, as carriers and adjuvant, can induce humoral and cellular immune responses.

5 | CONCLUSIONS

In conclusion, HMSNs can be used as delivery vehicle and adjuvant in VLP vaccine development. These particles not only help the antigen to be engulfed by phagocytosis but also retard antigen release to achieve a sustained immune response. However, although the amount of HMSNs used as vaccine adjuvant was significantly reduced, the biological residue requires further study.

ACKNOWLEDGMENTS

This study was supported by grants from the National Key Research and Development Program of China (2017YFD0500900, 2017YFD0501100, and 2016YFE0204100) and Elite Youth program of Chinese Academy of Agricultural Sciences.

CONFLICTS OF INTEREST

The authors declare that there are no conflicts of interest.

ORCID

Manyuan Bai http://orcid.org/0000-0001-5389-3699

REFERENCES

1. Alexandersen S, Mowat N. Foot-and-mouth disease: host range and pathogenesis. Curr Top Microbiol Immunol. 2005;288:9-42.
2. Alexandersen S, Zhang Z, Donaldson AI, Garland AJM. The pathogenesis and diagnosis of foot-and-mouth disease. J Com Pathol. 2003;129(1):1-36.
3. Yoon H, Jeong W, Han JH, et al. Financial impact of foot-and-mouth disease outbreaks on pig farms in the Republic of Korea, 2014/2015. Prev Vet Med. 2018;149:140-142.
4. Jemberu WT, Mureithi MC, Woldehanna T, Hogeveen H. Economic impact of foot and mouth disease outbreaks on smallholder farmers in Ethiopia. Prev Vet Med. 2014;116(1-2):26-36.
5. Knight-Jones TJ, Rushston J. The economic impacts of foot and mouth disease—what are they, how big are they and where do they occur? Prev Vet Med. 2013;112(3-4):161-173.
6. Veerapen VP, van Zyl AR, Wigdorovitz A, Rybicki EP, Meyers AE. Novel expression of immunogenic foot-and-mouth disease virus-like particles in Nicotiana benthamiana. Virus Res. 2017;244:213-217. Nov 30.
7. Cao Y, Lu Z, Sun J, et al. Synthesis of empty capsid-like particles of Asia I foot-and-mouth disease virus in insect cells and their immunogenicity in guinea pigs. Vet Microbiol. 2009;137(1-2):10-17.
8. Guo HC, Sun SQ, Jin Y, et al. Foot-and-mouth disease virus-like particles produced by a SUMO fusion protein system in Escherichia coli induce potent protective immune responses in guinea pigs, swine and cattle. Vet Res. 2013;44(48):48-61.
9. Paul S, Raul CO, Keith J. Control and eradication of foot-and-mouth disease. Virus Res. 2003;99:101-144.
10. Feng S, Patton M, Davis J. Market impact of foot-and-mouth disease control strategies: a UK case study. Front Vet Sci. 2017;4:129.

11. Neun BW, Dobrovolskaia MA. Analysis of nanoparticle-adjuvant properties in vivo. Methods Mol Biol. 2018;1682:189-195.

12. Liu Y, Miyoshi H, Nakamura M. Encapsulated ultrasound microbubbles: therapeutic application in drug/gene delivery. J Control Release. 2006;114(1):89-99.

13. Moghimi SM, Hunter AC, Murray JC. Nanomedicine: current status and future prospects. FASEB J. 2005;19(3):311-330.

14. Hafner AM, Corthésy B, Merkle HP. Particulate formulations for the delivery of poly(I:C) as vaccine adjuvant. Adv Drug Deliv Rev. 2013;65(10):1386-1399.

15. Teng X, Cheng S, Meng R, et al. A facile way for fabricating PEGylated hollow mesoporous silica nanoparticles and their drug delivery application. J Nanosci Nanotechnol. 2015;15(5):3773-3779.

16. Chakravarty R, Goel S, Hong H, et al. Hollow mesoporous silica nanoparticles for tumor vasculature targeting and PET image-guided drug delivery. Nanomedicine. 2015;10(8):1233-1246.

17. Mahony D, Cavallaro AS, Mody KT, et al. In vivo delivery of bovine viral diarrhea virus, E2 protein using hollow mesoporous silica nanoparticles. Nanoscale. 2014;6(12):6617-6626.

18. Teng Z, Han Y, Li J, Yan F, Yang W. Preparation of hollow mesoporous silica spheres by a sol-gel/emulsion approach. Micropor Mesopor Mat. 2010;17(1-2):67-72.

19. Lu BQ, Zhu YJ, Ao HY, Qi C, Chen F. Synthesis and characterization of magnetic iron oxide/calcium silicate mesoporous nanocomposites as a promising vehicle for drug delivery. ACS Appl Mater Inter. 2012;4(12):6969-6974.

20. Xu J, Guo HC, Wei YQ, et al. Self-assembly of virus-like particles of canine parvovirus capsid protein expressed from Escherichia coli and application as virus-like particle vaccine. Appl Microbial Biot. 2014;98(8):3529-3538.

21. Guo HC, Feng XM, Sun SQ, et al. Immunization of mice by hollow mesoporous silica nanoparticles as carriers of porcine circovirus type 2 ORF2 protein. Virol J. 2012;9:108.

22. Mahony D, Cavallaro AS, Stahr F, Mahony TJ, Qiao SZ, Mitter N. Mesoporous silica nanoparticles act as a self-adjuvant for ovalbumin model antigen in mice. Small. 2013;9(18):3138-3146.

23. Gregory A, Mayr VOD, Jarasvech C, Mason PW, Grubman MJ. Immune responses and protection against foot-and-mouth disease virus (FMDV) challenge in swine vaccinated with adenosivirus-FMDV constructs. Vaccine. 2001;19:2152-2161.

24. Shao J, Wang J, Chang H, Liu J. Immune potential of a novel multiple-epitope vaccine to FMDV type Asia 1 in guinea pigs and sheep. Virol Sin. 2011;26(3):190-197.

25. Roy P, Noad R. Virus-like particles as a vaccine delivery system: myths and facts. Hum Vaccin. 2008;4(1):5-12.

26. Noad R, Roy P. Virus-like particles as immunogens. Trends Microbiol. 2003;11(9):438-444.

27. Buonaguro L, Tornesello ML, Buonaguro FM. Virus-like particles as particulate vaccines. Curr HIV Res. 2010;8(4):299-309.

28. Ludwig C, Wagner R. Virus-like particles-universal molecular toolboxes. Curr Opin Biotech. 2007;18(6):537-545.

29. Chackerian B. Virus-like particles: flexible platforms for vaccine development. Exp Rev Vaccines. 2007;6(3):381-390.

30. Ferreira junior RS, Anderlini RP, Pimenta DC, de oliveira orsi R, Barrassi B, Sant’anna OA. New nanostructured silica adjuvant (SBA-15) employed to produce antivenom in young sheep using Crotalus durissus terrificus and Apis mellifera venoms detoxified by cobalt-60. J Toxicol Env Health A. 2010;73(13-14):926-933.

31. Skrastina D, Petrovskis I, Lieknina I, et al. Silica nanoparticles as the adjuvant for the immunisation of mice using hepatitis B core virus-like particles. PLOS. 2014;9(12):e114006.

32. Mody KT, Popat A, Mahony D, Cavallaro AS, Yu C, Mitter N. Mesoporous silica nanoparticles as antigen carriers and adjuvants for vaccine delivery. Nanoscale. 2013;5(12):5167-5179.

33. Kupferschmidt N, Qazi KR, Kemi C, et al. Mesoporous silica particles guide immune responses in guinea pigs. J Med Virol. 2019;91:6974.

34. Kalić P, Hilkens CMU, Wierenga EA, Kapsenberg ML. The concept of type 1 and type 2 antigen presentation. J Med Virol. 2010;82(1):184-188.

35. Martien L, Kapsenberg ML. T cell responses. Immunol Lett. 2019;2161:197.